Fidaxomicin use in the treatment of CDI has significantly increased since the IDSA 2021 Clinical Guideline Update; however, its use is still low.

Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Inclusion Criteria in the MyPEAKTM-1 Phase 1b/2 ...